0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......

Journal Articles

in Toxicology
 101-107 of 107 Articles
Commentary | 
James S. Goodwin, MD; Michael R. Tangum, MD
Arch Intern Med. 1998;158(20):2187-2191. doi:10.1001/archinte.158.20.2187.

Original Investigation |  FREE
Jimmy Dy Chua, MD; William R. Friedenberg, MD
Arch Intern Med. 1998;158(17):1929-1932. doi:10.1001/archinte.158.17.1929.

Original Investigation |  FREE
Mark H. Eckman, MD; Rodney H. Falk, MD; Stephen G. Pauker, MD
Arch Intern Med. 1998;158(15):1669-1677. doi:10.1001/archinte.158.15.1669.

Clinical Observation | 
Arthur Leibovitz, MD; Tamara Bilchinsky, MD; Israel Gil, MD; et al.
Arch Intern Med. 1998;158(10):1152-1153. doi:10.1001/archinte.158.10.1152.

Clinical Observation | 
Cristóbal Leonel Díaz-Sánchez, MD; Alberto Lifshitz-Guinzberg, MD; Gregorio Ignacio-Ibarra, MD; et al.
Arch Intern Med. 1998;158(8):925-927. doi:10.1001/archinte.158.8.925.

Clinical Observation | 
Barry Kirschbaum, MD
Arch Intern Med. 1998;158(4):405-408. doi:10.1001/archinte.158.4.405.

Review Article |  FREE
Peter R. Kowey, MD
Arch Intern Med. 1998;158(4):325-332. doi:10.1001/archinte.158.4.325.
Sign in to download this free article PDF

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Subscribe to the journal
From The JAMA Network
JAMA
Viewpoint  | 
Mandatory Use of Prescription Drug Monitoring Programs
Rebecca L. Haffajee, JD, MPH; Anupam B. Jena, MD, PhD; Scott G. Weiner, MD, MPH
JAMA
Viewpoint  | 
The Implications of Marijuana Legalization in Colorado
Andrew A. Monte, MD; Richard D. Zane, MD; Kennon J. Heard, MD, PhD
JAMA Dermatology
Case Report/Case Series  | 
MEK Inhibitor–Induced Dusky Erythema:  Characteristic Drug Hypersensitivity Manifestation in 3 Patients
Urvi Patel, MD; Lynn Cornelius, MD; Milan J. Anadkat, MD
JAMA Ophthalmology
Original Investigation  | 
Evaluation of Compounded Bevacizumab Prepared for Intravitreal Injection
Nicolas A. Yannuzzi, MD; Michael A. Klufas, MD; Lucy Quach, BS; et al.